Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism

HANGZHOU,China and SAN FRANCISCO,July 12,2023 -- Sciwind Biosciences Co.,Ltd.,a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease,today announced the publication of discovery,preclinical characterization,and Phase 1 clinical trial results of its GLP-1 analog ecnoglutide (XW003) in Molecular Metabolism.

Ecnoglutide is a novel,fatty acid-conjugated long-acting GLP-1 analog consisting of only natural amino acids,which simplifies the manufacturing process compared to some other GLP-1 analogs. In vitro,ecnoglutide showed potent activity that is biased towards cAMP induction over GLP-1 receptor internalization. In rodent models,ecnoglutide showed significant improvements in glycemic control and body weight reduction compared to semaglutide. In a Phase 1 clinical study,ecnoglutide was found to be generally safe and well tolerated with pharmacokinetic properties supporting once-weekly subcutaneous injections.

The full publication is available online at:

https://doi.org/10.1016/j.molmet.2023.101762

Ecnoglutide is currently being evaluated in Phase 3 clinical trials for the treatments of type 2 diabetes and obesity in China.

About ecnoglutide (XW003)

Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes,obesity,and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide is a novel,biased,long-acting GLP-1 peptide analog optimized for improved biological activity,cost-effective manufacturing,and once weekly dosing. Ecnoglutide has demonstrated treatment benefits for patients with type 2 diabetes and obesity and is safe and well tolerated in Phase 1 and Phase 2 clinical studies and is currently in multiple Phase 3 trials.

About Sciwind

Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates,including the long-acting GLP-1 peptide analog ecnoglutide (Phase 3),oral GLP-1 peptide analog XW004 (Phase 1),and oral small molecule GLP-1 receptor agonist XW014 (Phase 1). Sciwindhas developed multiple proprietary technologies,including oral peptide and inhaled protein therapeutic delivery platforms and identified a series of drug candidates based on these core platform technologies. For more information,visit www.sciwindbio.com.